Lymphoma, B-Cell
Conditions
Keywords
Lymphoma, Chimeric antigen receptor T cell, Chimeric antigen receptor, Immunotherapy, PD-1, CD19
Brief summary
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with relapsed/refractory B Cell Lymphoma.
Detailed description
Lymphoma is a malignant tumor originating from lymph nodes or other lymphoid tissues. It can be divided into B cells, T cells, and NK cell lymphomas depending on the origin of different lymphocytes. Among them, B cell lymphoma accounts for about 90% of lymphoma. Chimeric antigen receptor T (CART) cells is a promising treatment for lymphoma. T lymphocytes from patients are separated and engineered with CD19-CAR, to specifically recognize and eliminate CD19-positive tumor cells. At present, many CD19CART cells therapy studies are in the stage of clinical research and have achieved significant clinical effects. Although there are some CD9CART cells clinical trials, the therapeutic effect on lymphoma is significantly lower than that of acute leukemia. One of the reasons is that lymphoma has the nature of solid tumors, whichi has a certain immunosuppressive microenvironment. The clinical trials of anti-PD-1 antibody drugs against lymphoma also show good therapeutic efficacy. Therefore, the combination of anti-PD-1 or PD-L1 antibody and CD19CART is one of the ways to improve the therapeutic effect of CART cells. The investigators screened PD-1 mutants that have high bind with the PD-L1 ligand, and prepared CD19CART which secretes the mutant PD-1Fc fusion protein. Preclinical studies have shown that CD19CART cells secreting mutant PD-1Fc fusion protein have a superior killing effect to CD19CART cells which does not express PD-1 fusion protein. The trial was conducted to explore the safety and efficacy of CD19-PD1-CART cells in Relapsed/Refractory B Cell Lymphoma.
Interventions
BIOLOGICALCD19-PD1-CART Cell
This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
Sponsors
Chinese PLA General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided in 3 groups by different infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
Eligibility
Sex/Gender
ALL
Age
14 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, aged 14 to 80 years (including 14 and 80 years old). 2. The diagnosis was Refractory/relapsed B-cell lymphoma.(Meeting 1 of the first 4 items plus item 5) A.Tumor shrinkage less than 50% or disease progression after 4 cycles of standard chemotherapy. B.Achieved CR after standard chemotherapy, but relapsed within 6 months. C.2 or more relapses after CR. D.Not suitable for HSCT, or relapse after HSCT. E.Subjects must have received adequate treatment in the past and the predicted survival is more than three months. 3. Patient or his or her legal guardian voluntarily participates in this stuy and signs an informed consent form. 4. Flow cytometry or immunohistochemistry showed CD19 positive in tumor cells. 5. No serious concomitant disease and major organ function is not serious abnormal. 6. ECOG physical condition score 0-3 or KPS score \> 80. 7. the test meets the following indicators: A.ALT/AST \< 2.5 times the upper limit of normal (ULN) and total bilirubin≤34.2μmol/L. B.Creatinine \< 176.8 μmol/L. C.WBC≥2.5×109/L ，LY≥0.7×109/L，LY%≥15%. D.PT/INR \< 1.7 or PT was extended by less than 4 seconds.
Exclusion criteria
1. Women who are pregnant or breastfeeding. 2. Patients whose tumor cell don't have positive CD19 antigen. 3. Active hepatitis B or hepatitis C, HIV/AIDS infection, any uncontrolled active infection. 4. Patients who are using steroid drugs throughout the body currently. 5. Patients who have received any gene therapy in the past. 6. Patients who are allergy to immunotherapy and related drugs. 7. Patients with heavy heart disease or poorly controlled high blood pressure. 8. Patients who received chemotherapy or radiation 4 weeks before the study began. 9. Patients who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-related Adverse Events | 3 years | Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Remission Rate(ORR) of CD19-PD1-CART cells in Lymphoma | 3 years | ORR will be assessed from the first CAR-T cell infusion to death or last follow-up |
| Overall survival(OS) of CD19-PD1-CART cells in Lymphoma | 3 years | OS will be assessed from the first CAR-T cell infusion to death or last follow-up |
| Progress-free survival(PFS) of CD19-PD1-CART cells in Lymphoma | 3 years | PFS will be assessed from the first CAR-T cell infusion to death or last follow-up |
| Rate of CD19-PD1-CARTcells in peripheral blood cells | 3 years | In vivo (peripheral blood) rate of CD19-PD1-CART cells were determined by means of flow cytometry. |
| Quantity of CD19-PD1-CART cells copies in peripheral blood cells. | 3 years | In vivo (peripheral blood) quantity of CD19-PD1-CART cells copies copies were determined by means of qPCR. |
Countries
China
Contacts
Primary ContactQuanshun Wang
Backup ContactWenshuai Zheng
Outcome results
None listed